Founded in 2014, Yirdoc is a specialized developer of customized mesh nebulizer technologies for advanced inhalation drug delivery. Over the past decade, the company has focused on one clear mission: helping pharmaceutical partners improve inhalation therapy through precision-engineered aerosol delivery systems. Rather than treating the device as a standard accessory, Yirdoc views aerosol performance as an essential part of drug development strategy. Yirdoc’s core strength lies in customized mesh design for inhalation delivery. The company works to align nebulizer performance with the needs of specific formulations and therapeutic goals, supporting more effective and targeted drug delivery to the respiratory tract. This approach is especially relevant as inhalation therapies continue to expand beyond conventional respiratory products and into more complex and high-value treatment areas. In this context, device performance is no longer just a technical specification. It directly influences delivery efficiency, consistency, patient usability, and the overall development pathway of inhaled products. The company operates through a strategically structured platform that supports innovation, manufacturing, and global collaboration. Yirdoc’s R&D Center is located in Qingdao, where its engineering and development teams focus on advancing mesh nebulizer technology and improving aerosol delivery performance. Its manufacturing plant in Changsha provides the production capability needed to scale customized solutions with quality and reliability. To strengthen communication and cooperation with international partners, Yirdoc also maintains a branch office in Boston, allowing the company to stay close to the needs of the US and global pharmaceutical markets. Today, Yirdoc is supported by a team of approximately 70 engineers and specialists and generates annual revenue of around USD 15 million. This combination of technical talent, operational capability, and commercial growth reflects the company’s steady development as a focused player in inhalation drug delivery. Yirdoc is not positioned as a general device supplier. Instead, it aims to be a professional partner for pharmaceutical companies seeking tailored nebulization solutions and stronger integration between formulation and delivery technology. At ATS, Yirdoc is pleased to present its vision for the future of inhalation therapy: a future in which device design contributes directly to therapeutic success. By combining specialized mesh nebulizer technology, application-focused engineering, and a commitment to pharmaceutical innovation, Yirdoc supports the development of smarter and more effective inhalation solutions. With a foundation built on engineering expertise and a long-term focus on customized inhalation delivery, Yirdoc is committed to empowering pharmaceutical innovation through the subtle power of mesh technology.
Xentria, Inc.
Our name Xentria, derived from “centrality,” reflects our commitment to pioneering solutions in drug development. Our clinical-stage biotech collaborates with biopharmaceutical communities to tackle tough challenges in healthcare. Xentria is dedicated to advancing early-stage assets through clinical development, bringing them closer to commercialization. Xentria’s flagship asset, XTMAB-16, is an anti-TNFa mAb undergoing a Phase 2 trial for pulmonary sarcoidosis, a rare inflammatory disorder. Positioned as one of the few therapeutics developed specifically for this condition, XTMAB-16 signifies our dedication to addressing unmet needs. Xentria prioritizes collaboration and are open to partnering with commercial entities to provide accessible treatments for patients.
Vertex Pharmaceuticals
Vertex invests in scientific innovation to create transformative medicines for people with serious diseases. Through cutting-edge science across multiple modalities, it has approved medicines that treat the underlying causes of multiple diseases and conditions and has a broad and deep clinical pipeline. Learn more at www.vrtx.com. | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and IgA nephropathy. | xxx | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for serious kidney diseases, including APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy and autosomal dominant polycystic kidney disease.
Vasculitis Foundation
Vasculitis Foundation is the international organization for patients with vasculitis. Through its newsletter, website, information packets, 800 telephone number and symposia, the VF educates patients and family members about vasculitis. Our mission is to improve the diagnosis and treatment of vasculitis, increase awareness of vasculitis and support research to find the cause(s) and cure for vasculitis. www.VasculitisFoundation.org
UF Health Shands
The University of Florida’s Pulmonary, Critical Care, Lung Transplant, and Thoracic Programs form one of the nation’s premier destinations for complex lung and airway disease. As a high-volume referral center, UF provides advanced care for patients with the most challenging medical and surgical needs, including highly HLA-sensitized individuals, those requiring ECMO support, patients with multi-organ dysfunction, and adults or children needing lung or multi-organ transplantation. UF’s Pulmonary Vascular Disease Center and Rare Lung Disease Program delivers nationally recognized expertise across pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, lymphangioleiomyomatosis, and pulmonary alveolar proteinosis, each supported by accreditation as a Center of Excellence from leading national foundations. Integrated closely with thoracic surgery and cutting-edge research teams, these programs collectively drive innovation in diagnosis, therapeutics, and multidisciplinary care, establishing UF as a leading hub for advanced lung disease and transformative respiratory medicine.
Thirona
Thirona provides advanced lung image analysis with artificial intelligence through expertise-based services for MedTech, pharmaceutical and CRO companies. Thirona’s lung quantification platform LungQ® consists of a comprehensive portfolio of robust high-performance algorithms trained on a wide range of disease-specific datasets, offering market-leading AI analytical capabilities, with consistent and reproducible results. Integrated in multiple certified clinical end-products, our software is used by clinicians in more than 600 hospitals worldwide.